An immune based treatment would be so much better than chemo!
Seems that this is useful for non liver mets.
Objective responses:
- 24% overall response rate
73% disease control rate (partial response + stable disease)
50% objective responses with greater than 50% tumor reduction
- 80% objective responses ongoing at data cut-off
30% objective responses exceeding 1 year
Patient Sub-Populations:
Objective responses in 5 patients with RAS mutations for a 24% overall response rate and 81% disease control rate in this population; other PD-1 combinations in separate trials have reported only rare responses in this population (≤1% response rate)
Responses observed in patients with metastases historically resistant to immunotherapy, including patients with malignant pleural effusions, soft tissue, peritoneal, retroperitoneal, and bone metastases
Tolerability:
Botensilimab was well tolerated, with no grade 4/5 treatment-related adverse events
Rates of gastrointestinal and skin toxicities were comparable to those reported with first-generation CTLA-4 inhibitors
https://www.bakersfield.com/ap/news/agenus-shows-unprecedented-activity-for-botensilimab-balstilimab-combination-in-microsatellite/article_ce636aa6-c0d2-5443-a440-2128c8b5cfe0.html